The global market for RNAi technology is estimated US$ 8.7 billion in 2014 and is estimated to reach US$ 21.9 billion by 2019 with a CAGR of 20.19%
RNA interference (RNAi) is a natural process of treating forms of cancer and other diseases by post-transcriptional silencing of genes by small fragments of the nucleic acid. But the path of RNAi therapies to the clinic has been more like a roller-coaster ride. RNAi technology can be helpful in providing target specificity the proteins which lack the enzymatic pocket necessary for binding.
The major drivers for the growth of the market are improving synthetic delivery carriers and chemical modifications to RNA, Increasing genetic and metabolic disorders which includes diseases like cancer and cardiac and increasing applications in molecular diagnostics, particularly that of cancer. However, market is facing major challenges because of strict FDA regulations and the fact that RNA is potentially immunogenic and inherently unstable which causes major problems for the research and development of drugs. Greatly expanding the number of druggable disease targets and potentially streamlining drug development are the market growth opportunities in coming years.
RNAi technology is showing promise in treatment of viral infections like hepatitis B virus (HBV) which affects more than 300 million worldwide, killing at least 780,000 annually through liver scarring, liver failure and liver cancer. There has been a shift in strategic focus of RNAi innovators from RNAi triggers to delivery. Small RNAi therapeutics innovator (pure-play) companies and Big Pharma remain the industry’s two protagonists, although medium-sized pharmaceutical companies, including those in Asian countries, have taken some of the space vacated by Big Pharma. RNAi technology holds application in different sectors like drug discovery and development and therapeutics. Therapeutics is the major growing sector owing to the increased demand of treatment in cancer and liver disorders.
The market is segmented by type of application (Drug discovery and development, Therapeutics, and others), by therapeutics (oncology, ocular disorders, respiratory disorders, Liver diseases, and Neuronal disorders) and by geography (North America, Europe and Asia-Pacific).
The key players in the market are focused on expansion of the business by launching new products and extending the product line. Mergers and acquisitions of small and medium sized manufacturers to enter in overseas market is another strategy adopted by multinational players. RNAi technologies market is still at a nascent stage, but companies are keen on taking this market to a higher level. The major players in the market are Alnylam Pharmaceuticals, Quark Pharmaceuticals Inc, Benitec Biopharma Ltd, Qiagen, Invitrogen and Ambion.
What the Report Offers
1) Market definition of RNAi technology market along with identification of key drivers and restraints for the market.
2)Market analysis for the RNAi technology, with region specific assessments and competition analysis on a global and regional scale.
3)Identification of factors instrumental in changing the market scenarios, rising prospective opportunities and identification of key companies which can influence the market on a global and regional scale.
4)Extensively researched competitive landscape section with profiles of major companies along with their share of markets.
5)A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.
